• Cumberland corrected guidance on when it expects to release long-term safety and efficacy data from its Phase 2 FIGHT DMD open-label extension.
• A conference slide indicated the data was expected in August 2026.
• The company said the data is not yet available, no longer expects an August 2026 presentation, will present it later.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001087294-26-000064), on August 28, 2026, and is solely responsible for the information contained therein.